B7-H6在恶性肿瘤中的研究进展  

Research progress of B7-H6 in malignant tumors

作　　者：刘学静(综述) 徐燕颖(审校)[1] LIU Xuejing;XU Yanying(Department of Gynecology,The Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]天津医科大学第二医院妇科,天津300211

出　　处：《实用肿瘤学杂志》2021年第1期46-49,共4页Practical Oncology Journal

基　　金：天津医科大学第二医院青年科研基金项目(编号:2018ydey16)。

摘　　要：B7-H6是新近发现的免疫球蛋白超家族成员,是NK细胞表面活化性受体NKP30的膜结合配体。B7-H6较特异地表达于多种肿瘤组织,并且其表达水平与多种临床病理参数及预后显著相关。细胞表面B7-H6胞外域脱落后形成可溶性B7-H6,下调NKP30介导的NK细胞毒性及细胞因子的分泌。研究发现B7-H6通过蛋白酶抑制剂、Myc、异常的免疫应答、增殖和抗凋亡等调控机制促进恶性肿瘤的发生发展。目前对B7-H6基因的干预治疗是一种新型的肿瘤治疗策略,相关的免疫治疗正在探索中。总之,B7-H6已被证明是一种潜在的生物标志物和有价值的治疗靶点,可用于癌症的诊断、治疗和预后评估。B7-H6,a newly discovered member of the immunoglobulin superfamily,is the membrane-binding ligand of NKP30,which is an activated receptor of the NK cell surface.B7-H6 is specifically expressed in various tumor tissues,and its expression is significantly correlated with various clinicopathological parameters and prognosis.The tumor cell ectodomain shedding of B7-H6 forms soluble B7-H6(sB7-H6),which down-regulates NKp30-mediated NK cell cytotoxicity and cytokine secretion.Studies have found that B7-H6 promotes tumorigenesis via protease inhibitors,Myc,abnormal immune response,proliferation,and anti-apoptosis.At present,the intervention therapy of the B7-H6 gene is a new tumor treatment strategy,and related immunotherapy is being explored.In summary,B7-H6 has been proved to be a potential biomarker and valuable therapeutic target for the diagnosis,treatment,prognostic evaluation of cancer.

关 键 词：B7-H6 sB7-H6 NKP30 肿瘤免疫 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]